IV

Comera Life Sciences Expands Woburn Operations

Retrieved on: 
Tuesday, October 4, 2022

WOBURN, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the expansion of its Woburn, Mass. operations with a ribbon-cutting ceremony. The space at 12 Gill St. in Woburn, Mass., spans over 5,000 square feet and includes an expanded laboratory space for R&D activities as well as new executive offices.

Key Points: 
  • WOBURN, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the expansion of its Woburn, Mass.
  • The work of Comera Life Sciences seeks to directly address this barrier by providing a more convenient and equitable way to access these medications.
  • Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms.
  • To learn more about the Comera Life Sciences, visit comeralifesciences.com .

South Florida Sedation Dentistry Announces Launch Of New Website

Retrieved on: 
Tuesday, October 4, 2022

WEST PALM BEACH, Fla., Oct. 4, 2022 /PRNewswire-PRWeb/ -- South Florida Sedation Dentistry is announcing the launch of its new and improved website, https://www.southfloridasedationdentistry.com. The website has been redesigned to be more user-friendly, with core features that allow patients and visitors to get a wealth of information about the benefits of sedation dentistry and the other dental services offered in a quick and easy format. The website features a patient portal, which allows patients to easily access patient forms and communicate with their dentist through email. It also has testimonials from past and current patients as well as a Smile Gallery that showcases some of the smile makeovers performed by Dr. Senft and his dental team.

Key Points: 
  • South Florida Sedation Dentistry is announcing the launch of its new and improved website, southfloridasedationdentistry.com.
  • WEST PALM BEACH, Fla., Oct. 4, 2022 /PRNewswire-PRWeb/ -- South Florida Sedation Dentistry is announcing the launch of its new and improved website, https://www.southfloridasedationdentistry.com .
  • South Florida Sedation Dentistry is a leading provider of a range of dentistry services including implant, general, cosmetic, emergency, and sedation dentistry in South Florida.
  • South Florida Sedation Dentistry is located at 6633 Forest Hill Blvd, West Palm Beach, FL 33413.

Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

Retrieved on: 
Monday, October 3, 2022

KELOWNA, British Columbia, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the World Intellectual Property Organization (WIPO) published their international patent application (PCT/IB2022/052347) covering the intravenous administration of psilocybin and psilocin. The PCT application, titled “Improved Methods For The Use of Psychedelics” expands and strengthens the IP related to the Company’s development of TRP-8803, an IV formulation of psilocin, which will be administered in conjunction with psychotherapy.

Key Points: 
  • Psilocybin is a pro-drug which needs to be converted to psilocin, the active molecule that crosses the blood brain barrier and induces the psychedelic state.
  • These factors contribute to variable blood levels of psilocin, which can be either too low or too high.
  • Conversely, should the patient experience a side effect, the clinician can terminate administration of the drug, an option not available with oral administration.
  • Orally administered psychedelics have been widely introduced for use in treating depression, PTSD, OCD and other conditions, including by Tryp Therapeutics and its TRP-8802 programs.

SWK Holdings Enhances Executive Management Team and Expands Underwriting Team

Retrieved on: 
Monday, October 3, 2022

DALLAS, Oct. 3, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that the company has promoted Yvette Heinrichson to the role of Chief Financial Officer. Ms. Heinrichson was previously SWK's Chief Accounting Officer. SWK has also promoted John David ("J.D.") Tamas to Director of Underwriting, a newly created position at the company, and has hired Joe Moyer as an Associate.

Key Points: 
  • Mr. Staggs continued: "I would like to extend my sincerest gratitude to Charles Jacobson for his role in building SWK.
  • He has been a valued member of our leadership team since SWK's inception, and we wish him the best."
  • has an extensive credit background, and his enhanced role will allow SWK to increase underwriting throughput while maintaining strict credit standards.
  • He is a valuable member of our leadership team, and I'm pleased he is being recognized for his contributions to SWK."

Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population

Retrieved on: 
Monday, October 3, 2022

The evolution of Trogarzo administration from intravenous infusion to intravenous push means less preparation and treatment time in clinics for patients and their health care providers, possibly allowing for more clinics to administer this treatment.

Key Points: 
  • The evolution of Trogarzo administration from intravenous infusion to intravenous push means less preparation and treatment time in clinics for patients and their health care providers, possibly allowing for more clinics to administer this treatment.
  • We are proud of our long-term commitment to bring much needed non-oral innovations to help shift the treatment paradigm for heavily treatment-experienced people living with HIV.
  • Results show that the safety and PK profile of Trogarzo administered via IV push are similar to that of IV infusion administration.
  • Do not receive Trogarzo if you have had an allergic reaction to Trogarzo or any of the ingredients in Trogarzo.

Arizona IV Medics Announce Myers’ Cocktail As Their Best Selling IV Treatment The Past 6 Months

Retrieved on: 
Monday, October 3, 2022

Arizona IV Medics that are located at https://www.google.com/maps?ll=33.615878,-112.333003&z=7&t=m&hl=en&gl=US... and offer their mobile IV services in a 30 mile radius around the Phoenix, Tucson, Scottsdale, and Flagstaff areas.

Key Points: 
  • Arizona IV Medics that are located at https://www.google.com/maps?ll=33.615878,-112.333003&z=7&t=m&hl=en&gl=US... and offer their mobile IV services in a 30 mile radius around the Phoenix, Tucson, Scottsdale, and Flagstaff areas.
  • The nurses and paramedics at Arizona IV Medics provide supervised IV therapy with over 20 different vitamin ingredients, infusions, and injections, such as:
    Myers Cocktail Whether youre hungover, sick, or dehydrated, the Myers Cocktail is a popular choice for those searching for symptom relief.
  • The Arizona Exclusively offered by Arizona IV medics, this IV drip bag eliminates liver toxins, prevents kidney and liver damage, and is rich in saline, glutathione, and NAC.
  • To find out more about Arizona IV Medics and their popular Myers Cocktail or to read about their other IV packages, please visit their website at https://www.azivmedics.com/ .

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

Retrieved on: 
Friday, September 30, 2022

Retractable Technologies, Inc. (Retractable) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $19,061.25, respectively.

Key Points: 
  • Retractable Technologies, Inc. (Retractable) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $19,061.25, respectively.
  • The dividends cover the period beginning July 1, 2022 through September 30, 2022.
  • The dividends will be paid on October 21, 2022 to shareholders of record as of the close of business on October 11, 2022.
  • Retractable manufactures and markets VanishPoint and Patient Safe safety medical products and the EasyPoint needle.

Choose Ketamine Makes Transformative Psychedelic Therapy Accessible for More People

Retrieved on: 
Friday, September 30, 2022

However, it's only recently that organizations like Choose Ketamine have made the therapy widely available to people across the U.S.

Key Points: 
  • However, it's only recently that organizations like Choose Ketamine have made the therapy widely available to people across the U.S.
  • The cost of treatments, distance from a clinic and general discomfort prevented many people from being able to utilize this transformative psychedelic therapy.
  • Choose Ketamine is changing that with at home ketamine treatments that are safe, affordable, effective and convenient.
  • Currently, affordable at-home ketamine treatments are available from Choose Ketamine in the following states :

Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma

Retrieved on: 
Friday, September 30, 2022

Preclinical results were featured in an oral presentation at the SIOP 2022 Congress of the International Society of Pediatric Oncology, being held in Barcelona, Spain from September 28-October 1, 2022.

Key Points: 
  • Preclinical results were featured in an oral presentation at the SIOP 2022 Congress of the International Society of Pediatric Oncology, being held in Barcelona, Spain from September 28-October 1, 2022.
  • The exciting new data presented at SIOP demonstrate that administration of VCN-01 in combination with topotecan chemotherapy may improve VCN-01 activity against retinoblastoma, said Manel Cascall, Ph.D., General Director of Synthetic Biologics European Subsidiary.
  • Sequential administration of intratumoral VCN-01 followed by systemic topotecan significantly increased median ocular survival, compared to VCN-01 alone (p =0.0364).
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need.

AVA, B. Braun Partnership Continues to Raise Standards for PIV Education and Training with Launch of New Certificate Course on Vascular Access

Retrieved on: 
Thursday, September 29, 2022

BETHLEHEM, Pa., Sept. 29, 2022 /PRNewswire/ -- Today B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, together with the Association for Vascular Access (AVA), announced the launch of The Fundamentals of Peripheral IV Access eLearning Program©. This robust eLearning curriculum consists of multiple comprehensive certificate courses focusing on the basic, intermediate and advanced concepts in vascular access and improving patient outcomes. The curriculum also includes a course focused specifically on pediatric and neonatal peripheral intravenous insertion and care.

Key Points: 
  • This robust eLearning curriculum consists of multiple comprehensive certificate courses focusing on the basic, intermediate and advanced concepts in vascular access and improving patient outcomes.
  • "AVA is committed to providing comprehensive education and training on vascular access to improve patient safety and outcomes," said Judy Thompson, MSNEd, RN, VA-BC, AVA Director of Clinical Education.
  • "We're proud of the collaboration with AVA to advance vascular access education and training to help healthcare providers improve the standard of vascular access care for patients."
  • "The failure rate of PIVC insertions is not acceptable," said David Banko, Director, Health Economics and Outcomes Research, B. Braun.